Compare Aurobindo Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ORCHID PHARMA LTD - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ORCHID PHARMA LTD AUROBINDO PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 8.9 -0.4 - View Chart
P/BV x 1.6 0.1 1,392.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 AUROBINDO PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ORCHID PHARMA LTD
Sep-13
AUROBINDO PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs830194 427.8%   
Low Rs52735 1,506.0%   
Sales per share (Unadj.) Rs333.9276.5 120.8%  
Earnings per share (Unadj.) Rs40.4-79.2 -50.9%  
Cash flow per share (Unadj.) Rs51.8-43.5 -119.1%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.153.9 439.5%  
Shares outstanding (eoy) m585.9170.45 831.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.00.4 490.7%   
Avg P/E ratio x16.8-1.4 -1,163.2%  
P/CF ratio (eoy) x13.1-2.6 -497.5%  
Price / Book Value ratio x2.92.1 134.8%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5698,067 4,928.6%   
No. of employees `00017.92.8 637.7%   
Total wages/salary Rs m25,8492,527 1,022.9%   
Avg. sales/employee Rs Th10,956.96,956.1 157.5%   
Avg. wages/employee Rs Th1,447.7902.5 160.4%   
Avg. net profit/employee Rs Th1,324.3-1,993.0 -66.4%   
INCOME DATA
Net Sales Rs m195,63619,477 1,004.4%  
Other income Rs m1,553407 381.4%   
Total revenues Rs m197,18919,884 991.7%   
Gross profit Rs m39,5191,103 3,584.2%  
Depreciation Rs m6,6802,519 265.1%   
Interest Rs m2,6265,227 50.2%   
Profit before tax Rs m31,767-6,236 -509.4%   
Minority Interest Rs m2720 137.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881511 -172.3%   
Tax Rs m7,269-125 -5,805.5%   
Profit after tax Rs m23,645-5,580 -423.7%  
Gross profit margin %20.25.7 356.8%  
Effective tax rate %22.92.0 1,139.7%   
Net profit margin %12.1-28.7 -42.2%  
BALANCE SHEET DATA
Current assets Rs m153,64511,014 1,395.0%   
Current liabilities Rs m120,42932,060 375.6%   
Net working cap to sales %17.0-108.1 -15.7%  
Current ratio x1.30.3 371.4%  
Inventory Days Days13595 142.5%  
Debtors Days Days6434 189.8%  
Net fixed assets Rs m103,90929,440 353.0%   
Share capital Rs m586705 83.2%   
"Free" reserves Rs m138,3222,043 6,771.9%   
Net worth Rs m138,9083,800 3,655.6%   
Long term debt Rs m1,8009,018 20.0%   
Total assets Rs m264,54446,510 568.8%  
Interest coverage x13.1-0.2 -6,781.9%   
Debt to equity ratio x02.4 0.5%  
Sales to assets ratio x0.70.4 176.6%   
Return on assets %9.9-0.8 -1,306.6%  
Return on equity %17.0-146.9 -11.6%  
Return on capital %23.8-3.7 -638.2%  
Exports to sales %49.637.9 131.0%   
Imports to sales %18.822.6 83.0%   
Exports (fob) Rs m97,0917,378 1,316.0%   
Imports (cif) Rs m36,7414,406 833.9%   
Fx inflow Rs m97,3167,513 1,295.3%   
Fx outflow Rs m40,5895,649 718.5%   
Net fx Rs m56,7271,865 3,042.5%   
CASH FLOW
From Operations Rs m16,2201,682 964.5%  
From Investments Rs m-28,768-9,860 291.8%  
From Financial Activity Rs m19,1916,644 288.8%  
Net Cashflow Rs m6,656-1,535 -433.6%  

Share Holding

Indian Promoters % 54.1 32.3 167.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.6 172.8%  
FIIs % 27.7 3.3 839.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.2 55.3 18.4%  
Shareholders   69,601 84,811 82.1%  
Pledged promoter(s) holding % 8.6 54.9 15.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 1,375 Points; Nifty Ends Below 8,300 Mark(Closing)

Indian share markets witnessed selling pressure throughout the day and ended deep in the red with Sensex and Nifty witnessing a sharp fall during closing hours.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 30, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS